Back-up bone marrow is frequently ineffective in patients with poor peripheral-blood stem-cell mobilization

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
M J WattsD C Linch

Abstract

To assess hematologic recovery and procedure-related mortality in patients who received high-dose therapy with stem-cell support, in whom the peripheral-blood stem-cell (PBSC) collection fails (CD34+ cells < 1 x 10(6)/kg). The predictive value of granulocyte-monocyte colony-forming cell (GM-CFC) measurements and the value of bone marrow obtained after PBSC collection failure was assessed. The study group comprised 324 consecutive patients mobilized with granulocyte colony-stimulating factor (G-CSF) and cyclophosphamide (273 patients), G-CSF with other chemotherapy (37 patients), and G-CSF alone (14 patients). Between one and four aphereses were performed. In 51 of 324 patients, there was failure to obtain 1 x 10(6)/kg CD34+ cells. Twenty-three patients had greater than 1 x 10(5)/kg GM-CFC; 22 patients proceeded to high-dose therapy. Neutrophil recovery occurred within 21 days, but platelet independence was delayed (> 28 days) in eight patients. Of 28 patients with less than 1 x 10(5)/kg GM-CFC, six received high-dose therapy with PBSC alone and five had delayed engraftment. Twelve patients with less than 1 x 10(5)/kg GM-CFC received high-dose therapy supported by bone marrow collected after PBSC collection failure. Eleven patie...Continue Reading

Citations

Mar 14, 2003·Bone Marrow Transplantation·A Kessinger, J G Sharp
Feb 15, 2001·Journal of Hematotherapy & Stem Cell Research·J G SharpS S Joshi
Aug 27, 2010·European Journal of Haematology·Esa Jantunen, Gunnar Kvalheim
May 21, 2011·International Journal of Hematology·Shinichiro MoriSusumu Ikehara
Feb 1, 2013·Transfusion·Yvette C TanhehcoUna O'Doherty
Oct 18, 2016·British Journal of Haematology·Michael J Watts, David C Linch
Jun 25, 2016·British Journal of Haematology·Peter Hokland, Finbarr Cotter
Aug 13, 2011·Blood·L Bik ToKirsten E Herbert
Jan 27, 2009·Journal of Clinical Apheresis·Maria Juliana MajadoAlfonso Morales
Mar 3, 2004·Cytometry. Part a : the Journal of the International Society for Analytical Cytology·Michael KeeneyD Robert Sutherland
Jan 10, 2008·European Journal of Haematology·Esa Jantunen, Taru Kuittinen
Oct 13, 2020·Journal of Clinical Apheresis·Hideki GotoUNKNOWN North Japan Hematology Study Group (NJHSG)
Nov 30, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S LimatUNKNOWN Groupe Ouest Est d'étude des Leucémies et Autres Maladies du Sang (GOELAMS)
Dec 22, 2000·Blood Reviews·S Fu, J Liesveld

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
W I BensingerC D Buckner
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
P J BiermanJ O Armitage
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
M W DercksenC E van der Schoot
© 2022 Meta ULC. All rights reserved